AERI Aerie Pharmaceuticals Inc

Price (delayed)

$16.01

Market cap

$749.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.18

Enterprise value

$840.47M

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The company's revenue rose by 39% YoY
AERI's EPS is up by 5% from the previous quarter and by 2.8% YoY
The gross profit has increased by 12% year-on-year but it has declined by 2.8% since the previous quarter
AERI's equity has dropped by 71% year-on-year and by 33% since the previous quarter
AERI's quick ratio is down by 42% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of AERI
Market
Shares outstanding
46.81M
Market cap
$749.5M
Enterprise value
$840.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.39
Price to sales (P/S)
8.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.11
Earnings
Revenue
$83.11M
EBIT
-$192.06M
EBITDA
-$158.71M
Free cash flow
-$118.73M
Per share
EPS
-$4.18
Free cash flow per share
-$2.58
Book value per share
$1.29
Revenue per share
$1.81
TBVPS
$7.98
Balance sheet
Total assets
$366.69M
Total liabilities
$306.59M
Debt
$220.75M
Equity
$60.1M
Working capital
$206.57M
Liquidity
Debt to equity
3.67
Current ratio
3.33
Quick ratio
2.99
Net debt/EBITDA
-0.57
Margins
EBITDA margin
-191%
Gross margin
75.4%
Net margin
-231%
Operating margin
-204.6%
Efficiency
Return on assets
-47.5%
Return on equity
-173%
Return on invested capital
-48.8%
Return on capital employed
-69.1%
Return on sales
-231.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AERI stock price

How has the Aerie Pharmaceuticals stock price performed over time
Intraday
6.24%
1 week
12.19%
1 month
21.47%
1 year
-29.6%
YTD
18.5%
QTD
18.5%

Financial performance

How have Aerie Pharmaceuticals's revenue and profit performed over time
Revenue
$83.11M
Gross profit
$62.63M
Operating income
-$170.04M
Net income
-$192.03M
Gross margin
75.4%
Net margin
-231%
The company's revenue rose by 39% YoY
The operating margin has grown by 36% YoY and by 7% from the previous quarter
Aerie Pharmaceuticals's net margin has increased by 30% YoY and by 7% from the previous quarter
AERI's gross margin is down by 20% year-on-year and by 4.6% since the previous quarter

Growth

What is Aerie Pharmaceuticals's growth rate over time

Valuation

What is Aerie Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.39
P/S
8.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.11
AERI's EPS is up by 5% from the previous quarter and by 2.8% YoY
The P/B is 75% above the last 4 quarters average of 7.1 and 25% above the 5-year quarterly average of 9.9
AERI's equity has dropped by 71% year-on-year and by 33% since the previous quarter
The company's revenue rose by 39% YoY
The price to sales (P/S) is 8% less than the last 4 quarters average of 9.6

Efficiency

How efficient is Aerie Pharmaceuticals business performance
Aerie Pharmaceuticals's ROE has plunged by 73% YoY and by 27% from the previous quarter
The ROIC has soared by 66% YoY and by 5% from the previous quarter
AERI's ROS is up by 30% YoY and by 7% from the previous quarter
The ROA has grown by 24% YoY

Dividends

What is AERI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AERI.

Financial health

How did Aerie Pharmaceuticals financials performed over time
Aerie Pharmaceuticals's total assets is 20% higher than its total liabilities
AERI's quick ratio is down by 42% year-on-year and by 12% since the previous quarter
The current ratio has declined by 39% year-on-year and by 11% since the previous quarter
AERI's equity has dropped by 71% year-on-year and by 33% since the previous quarter
Aerie Pharmaceuticals's debt has increased by 10% YoY and by 2.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.